Novo Nordisk and NanoVation sign $600m deal in rare and …
WEB1 day ago · NVO. GLDAF. Novo Nordisk has signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases. Novo has secured a licence to use NanoVation’s long ...
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity …
WEB16 hours ago · Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients. The Danish pharmaceutical giant said late Thursday ...
News Details - novonordisk.com
WEB1 day ago · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to …
Novo Nordisk bets $600M biobucks on NanoVation's ability to …
WEB2 days ago · Novo Nordisk's latest RNA deal involves $530M biobucks to sing in Korro's opera. Novo is paying an upfront fee of undisclosed size to enter into the collaboration. Factoring in milestones, the ...
Latest news - Novo Nordisk
WEB10 July 2024. Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec. Read more. News archive. Featured stories. PRODUCTION. Expanding our fill-finish capacity.
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Novo Nordisk signs deals worth up to $1bn with US biotechs in …
WEBJan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...
News Details - Novo Nordisk
WEBMar 5, 2024 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW.
Novo Nordisk Just Took a $530 Million Step Onto Moderna's …
WEB1 day ago · Novo Nordisk's deal with Korro is worth a total of $530 million in funding, milestone payments, royalties, and up-front payments to get the ball rolling. That makes the agreement a meaty but ...
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian …
WEB1 day ago · Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the development of novel genetic medicines targeting cardiometabolic ...